Dysgeusia in patients with advanced urothelial carcinoma receiving enfortumab vedotin, platinum-based chemotherapy, or immune check point inhibitors: time-course assessment using chemotherapy-induced taste alteration scale

被引：2

作者：

Miyake, Makito ^{[1
]}

Nishimura, Nobutaka ^{[1
]}

Oda, Yuki ^{[1
]}

Miyamoto, Tatsuki ^{[1
]}

Tomizawa, Mitsuru ^{[1
]}

Shimizu, Takuto ^{[1
]}

Hori, Shunta ^{[1
]}

Morizawa, Yosuke ^{[1
]}

Gotoh, Daisuke ^{[1
]}

Nakai, Yasushi ^{[1
]}

Torimoto, Kazumasa ^{[1
]}

Fujii, Tomomi ^{[2
,3
]}

Tanaka, Nobumichi ^{[1
,4
]}

Fujimoto, Kiyohide ^{[1
]}

机构：

[1] Nara Med Univ, Dept Urol, 840 Shijo cho, Kashihara, Nara 6348522, Japan

[2] Nara Med Univ, Dept Diagnost Pathol, Kashihara, Nara, Japan

[3] Osaka Univ, Ctr Infect Dis Educ & Res CiDER, Div Fostering Required Med Human Resources, Osaka, Japan

[4] Nara Med Univ, Dept Prostate Brachytherapy, Kashihara, Nara, Japan

来源：

JOURNAL OF CHEMOTHERAPY | 2025年 / 37卷 / 02期

关键词：

Chemotherapy; dysgeusia; enfortumab vedotin; patient reported outcome measures; urothelial carcinoma; BREAST-CANCER; SMELL CHANGES; DYSFUNCTION; JAPANESE; VERSION;

D O I：

10.1080/1120009X.2024.2340885

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A time-course questionnaire survey using the chemotherapy-induced taste alteration scale (CiTAS) was conducted in patients with advanced urothelial carcinoma (UC) treated with systemic chemotherapy and/or immunotherapy. A total of 37 patients receiving systemic therapy with enfortumab vedotin (EV), platinum-based chemotherapy and immune checkpoint inhibitors were included in this study. No significant changes were observed in any of the CiTAS subscales during platinum-based chemotherapy and immune checkpoint inhibitor treatment, while EV therapy induced significant dysgeusia. Among 10 patients treated with EV, dysgeusia was associated with a substantial negative effect on the health-related quality-of-life domains, particularly global health status/QOL (mean +/- standard deviation: 52 +/- 19 in dysgeusia group vs 89 +/- 13 in non-dysgeusia group) and mental component summary (47 +/- 5.1 vs 53 +/- 2.0). The fatigue symptom score was higher in the dysgeusia group at the post-third cycle of EV (47 +/- 16 vs 15 +/- 17). Severe dysgeusia can be induced by EV therapy, which is usually not observed in other systemic therapies for advanced UC.

引用

页码：146 / 158

页数：13

共 41 条

[1] Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03) [J].

Bamias, A. ;

Dafni, U. ;

Karadimou, A. ;

Timotheadou, E. ;

Aravantinos, G. ;

Psyrri, A. ;

Xanthakis, I. ;

Tsiatas, M. ;

Koutoulidis, V. ;

Constantinidis, C. ;

Hatzimouratidis, C. ;

Samantas, E. ;

Visvikis, A. ;

Chrisophos, M. ;

Stravodimos, K. ;

Deliveliotis, C. ;

Eleftheraki, A. ;

Pectasides, D. ;

Fountzilas, G. ;

Dimopoulos, M. A. .

ANNALS OF ONCOLOGY, 2013, 24 (04) :1011-1017

[2] Self-reported taste and smell changes during cancer chemotherapy [J].

Bernhardson, Britt-Marie ;

Tishelman, Carol ;

Rutqvist, Lars E. .

SUPPORTIVE CARE IN CANCER, 2008, 16 (03) :275-283

[3] Chemosensory changes experienced by patients undergoing cancer chemotherapy: A qualitative interview study [J].

Bernhardson, Britt-Marie ;

Tishelman, Carol ;

Rutqvist, Lars Erik .

JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2007, 34 (04) :403-412

[4] Taste and smell dysfunction in patients receiving chemotherapy: a review of current knowledge [J].

Comeau, TB ;

Epstein, JB ;

Migas, C .

SUPPORTIVE CARE IN CANCER, 2001, 9 (08) :575-580

[5] Effects of drugs on olfaction and taste [J].

Doty, RL ;

Bromley, SM .

OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA, 2004, 37 (06) :1229-+

[6] Chemotherapy-induced taste and smell changes influence food perception in cancer patients [J].

Drareni, K. ;

Bensafi, M. ;

Giboreau, A. ;

Dougkas, A. .

SUPPORTIVE CARE IN CANCER, 2021, 29 (04) :2125-2132

[7] Relationship between food behavior and taste and smell alterations in cancer patients undergoing chemotherapy: A structured review [J].

Drareni, Kenza ;

Dougkas, Anestis ;

Giboreau, Agnes ;

Laville, Martine ;

Souquet, Pierre-Jean ;

Bensafi, Moustafa .

SEMINARS IN ONCOLOGY, 2019, 46 (02) :160-172

[8]

EAU Guidelines, 2023, EAU ANN C MILAN

[9] Understanding the impact of taste changes in oncology care [J].

Epstein, Joel B. ;

Smutzer, Gregory ;

Doty, Richard L. .

SUPPORTIVE CARE IN CANCER, 2016, 24 (04) :1917-1931

[10] Taste disorders in cancer patients: Pathogenesis, and approach to assessment and management [J].

Epstein, Joel B. ;

Barasch, Andrei .

ORAL ONCOLOGY, 2010, 46 (02) :77-81

← 1 2 3 4 5 →